Yantai Dongcheng Pharmaceutical GroupLtd Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Zhi Gang Luo

Chief Executive Officer (CEO)

CN¥2.0m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	3.8yrs
Participación del CEO	0.6%
Permanencia media de la dirección	3.8yrs
Promedio de permanencia en la Junta Directiva	3.8yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Zhi Gang Luo (54 yo)

3.8yrs

Permanencia

CN¥2,023,200

Compensación

Mr. Zhi Gang Luo serves as a Non-Independent Director at Yantai Dongcheng Pharmaceutical Group Co., Ltd. since January 22, 2021 and serves as its General Manager. He was a Deputy General Manager at Yantai...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Zhi Gang Luo	GM & Non-Independent Director	no data	CN¥2.02m	0.60% CN¥ 66.1m
Chun Zhu	Financial Director	16.9yrs	CN¥894.50k	0.0052% CN¥ 581.6k
Xiao Liu	Deputy GM	5.1yrs	CN¥1.53m	sin datos
Chun Xiang Lu	Deputy General Manager	2.6yrs	CN¥439.80k	0.00038% CN¥ 42.2k
Chao Wang	Accounting Supervisor	no data	sin datos	sin datos
NA NA	Deputy General Manager	1.9yrs	sin datos	sin datos
Xiaoming Wu	Deputy General Manager	3.8yrs	sin datos	sin datos
Jing Sun	Deputy General Manager	3.8yrs	sin datos	sin datos

3.8yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 002675 se considera experimentado (3.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Zhi Gang Luo	GM & Non-Independent Director	3.8yrs	CN¥2.02m	0.60% CN¥ 66.1m
Xiao Liu	Deputy GM	2.5yrs	CN¥1.53m	sin datos
Dayong Zhao	Independent Director	3.8yrs	CN¥70.00k	sin datos
Shouyi You	Chairman	10.8yrs	CN¥1.80m	12.53% CN¥ 1.4b
Hongtao Sun	Supervisor	10.8yrs	sin datos	0.0020% CN¥ 224.2k
Qinglin Liu	Chairman of the Supervisory Board	no data	sin datos	sin datos
Fang Li	Independent Director	3.8yrs	CN¥70.00k	sin datos
Qingbao Yang	Supervisor	2.6yrs	sin datos	sin datos

3.8yrs

Permanencia media

53.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 002675 se considera experimentada (3.8 años de antigüedad promedio).

Yantai Dongcheng Pharmaceutical GroupLtd Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Yantai Dongcheng Pharmaceutical Group Co.,Ltd., Annual General Meeting, May 17, 2024

Yantai Dongcheng Pharmaceutical Group Co.,Ltd., Annual General Meeting, May 17, 2024

High number of new and inexperienced directors

Yantai Dongcheng Pharmaceutical Group Co.,Ltd., Annual General Meeting, May 19, 2023

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Announces Executive Changes

Recent updates

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Proposes Dividend for the Third Quarter of 2024

Third quarter 2024 earnings released: EPS: CN¥0.067 (vs CN¥0.12 in 3Q 2023)

Investor sentiment deteriorates as stock falls 15%

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Second quarter 2024 earnings released: EPS: CN¥0.058 (vs CN¥0.16 in 2Q 2023)

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Yantai Dongcheng Pharmaceutical Group Co.,Ltd., Annual General Meeting, May 17, 2024

Full year 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.38 in FY 2022)

Yantai Dongcheng Pharmaceutical Group Co.,Ltd., Annual General Meeting, May 17, 2024

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Investor sentiment improves as stock rises 17%

Investor sentiment deteriorates as stock falls 15%

Now 25% undervalued after recent price drop

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

Now 21% undervalued

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.20 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.14 in 2Q 2022)

High number of new and inexperienced directors

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 10 July 2023

Now 21% undervalued after recent price drop

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Approves Cash Dividend for 2022

Yantai Dongcheng Pharmaceutical Group Co.,Ltd., Annual General Meeting, May 19, 2023

First quarter 2023 earnings released: EPS: CN¥0.061 (vs CN¥0.069 in 1Q 2022)

Now 21% undervalued

Third quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.13 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.11 in 2Q 2021)

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Announces Final Cash Dividend on A Shares for 2021, Payable on 09 June 2022

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Approves Cash Dividend for the Year 2021

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Proposes Final Cash Dividend for the Year 2021

First quarter 2022 earnings released: EPS: CN¥0.069 (vs CN¥0.083 in 1Q 2021)

Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.15 in 3Q 2020)

Yantai Dingying Investment Partnership (Limited) Partnership) and Chen Xiaoyuan acquired 25% stake in Shanghai Lannacheng Biotechnology Co., Ltd. from Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (SZSE:002675) and Xu Ye.

Second quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.18 in 2Q 2020)

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Approves Cash Dividend for the Year 2020, Payable on 4 June 2021

First quarter 2021 earnings released: EPS CN¥0.083 (vs CN¥0.092 in 1Q 2020)

New 90-day low: CN¥18.22

New 90-day low: CN¥18.29

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Announces Executive Changes

New 90-day low: CN¥19.30

New 90-day low: CN¥21.28

New 90-day high: CN¥25.90

Third quarter earnings released

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. to Report Q3, 2020 Results on Oct 27, 2020

First half earnings released

New 90-day high - CN¥27.24

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. to Report First Half, 2020 Results on Aug 07, 2020

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad